Med Ed Report briefs

Share this article:
The Obama administration is proposing a measure that would make the recommendations of the Medicare Policy Advisory Committee on cost reductions policy. Obama told the AMA: “In recent years, this commission proposed roughly $200 billion in savings that never made it into law. These recommendations have now been incorporated into our broader reform agenda, but we need to fast-track their proposals in the future so that we don't miss another opportunity to save billions of dollars.”

ScopeMedical, a UK-based medical communications company, has opened a US outpost in Princeton, NJ. The 15-year-old company, which boasts a staff of 55, is led by CEO Jeremy Williams, who said the firm was expanding to the US in response to client demand.

Vermont's harsh law regarding gifts to physicians and other financial relationships between healthcare professionals and drug companies takes effect this month. The law allows for honoraria to CME speakers, but with many strings attached. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?